RANJANA K KANCHAN

Dr. RANJANA K KANCHAN

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Jyoti Bala KaushalJyoti Bala Kaushal
Jyoti Bala Kaushal
RBRakesh Bhatia
Rakesh Bhatia
RKRANJANA K KANCHAN
RANJANA K KANCHAN
PRPratima Raut
Pratima Raut
SMSurya K. Mallapragada
Surya K. Mallapragada
SRSatyanarayana Rachagani
Satyanarayana Rachagani
Niclosamide (Nic), an FDA-approved anthelmintic drug, is reported to have anti-cancer efficacy and is being assessed in clinical trials for various solid tumors. Based on its ability to target multiple signaling pathways, in the present study, we evaluated the therapeutic efficacy of Nic on pancreatic cancer (PC) in vitro. We observed an anti-cancerous effect of this drug as shown by the G0/G1 phase cell cycle arrest, inhibition of PC cell viability, colony formation, and migration. Our results revealed the involvement of mitochondrial stress and mTORC1-dependent autophagy as the predominant players of Nic-induced PC cell death. Significant reduction of Nic-induced reactive oxygen species (ROS) and cell death in the presence of a selective autophagy inhibitor spautin-1 demonstrated autophagy as a major contributor to Nic-mediated cell death. Mechanistically, Nic inhibited the interaction between BCL2 and Beclin-1 that supported the crosstalk of autophagy and apoptosis. Further, Nic treatment resulted in Gsk3β inactivation by phosphorylating its Ser-9 residue leading to upregulation of Sufu and Gli3, thereby negatively impacting hedgehog signaling and cell survival. Nic induced autophagic cell death, and p-Gsk3b mediated Sufu/Gli3 cascade was further confirmed by Gsk3β activator, LY-294002, by rescuing inactivation of Hh signaling upon Nic treatment. These results suggested the involvement of a non-canonical mechanism of Hh signaling, where p-Gsk3β acts as a negative regulator of Hh/Gli1 cascade and a positive regulator of autophagy-mediated cell death. Overall, this study established the therapeutic efficacy of Nic for PC by targeting p-Gsk3β mediated non-canonical Hh signaling and promoting mTORC1-dependent autophagy and cell death.

1 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SGShailendra Gautam
Shailendra Gautam
RKRANJANA K KANCHAN
RANJANA K KANCHAN
Jawed A SiddiquiJawed A Siddiqui
Jawed A Siddiqui
SMShailendra Kumar Maurya
Shailendra Kumar Maurya
SRSanchita Rauth
Sanchita Rauth
Mohd NasserMohd Nasser
Mohd Nasser
Brain metastasis (BrM) remains a significant cause of cancer-related mortality in epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) patients. We proposed here that a combination treatment of irreversible tyrosine kinase inhibitor neratinib (NER) and the c-MET inhibitor cabozantinib (CBZ) could prevent brain metastasis. To address this, we first tested the combination treatment of NER and CBZ in the brain-seeking ERBB2+ cell lines SKBrM3 and JIMT-1-BR3, and in ERBB2+ organoids that expressed the c-MET/ERBB1 axis. Next, we developed and characterized an orthotopic mouse model of spontaneous BrM and evaluated the therapeutic effect of CBZ and NER in vivo. The combination treatment of NER and CBZ significantly inhibited proliferation and migration in ERBB2+ cell lines and reduced the organoid growth in vitro. Mechanistically, the combination treatment of NER and CBZ substantially inhibited ERK activation downstream of the c-MET/ERBB1 axis. Orthotopically implanted SKBrM3+ cells formed primary tumor in the mammary fat pad and spontaneously metastasized to the brain and other distant organs. Combination treatment with NER and CBZ inhibited primary tumor growth and predominantly prevented BrM. In conclusion, the orthotopic model of spontaneous BrM is clinically relevant, and the combination therapy of NER and CBZ might be a useful approach to prevent BrM in BC.

9 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Jyoti Bala KaushalJyoti Bala Kaushal
Jyoti Bala Kaushal
RBRakesh Bhatia
Rakesh Bhatia
RKRANJANA K KANCHAN
RANJANA K KANCHAN
PRPratima Raut
Pratima Raut
SMSurya K. Mallapragada
Surya K. Mallapragada
SRSatyanarayana Rachagani
Satyanarayana Rachagani
The authors would like to make a correction to their published paper